


AstraZeneca Pharma India Limited
Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045
Financial results for the quarter ended 30 June 2016

Part I		Rs in lakhs (except for number of shares)			
Statement of unaudited results for the quarter ended 30 June 2016					
SI No.	Particulars	3 months ended 30/06/2016 (Unaudited)	3 months ended 31/03/2016 (Audited) ⁴	3 months ended 30/06/2015 (Unaudited)	Year ended 31/03/2016 (Audited)
1	Income from operations				
	a) Net sales/ income from operations (net of excise duty)	13,809.23	13,351.48	12,003.12	52,645.98
	b) Other operating income	144.85	2,530.56	1,194.56	3,727.25
	Total income from operations (net)	13,954.08	15,882.04	13,197.68	56,373.23
2	Expenses				
	(a) Cost of materials consumed	319.83	868.74	920.10	3,475.85
	(b) Purchase of stock-in-trade	5,077.90	4,821.39	3,130.79	15,888.71
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(922.85)	(521.24)	592.42	541.52
	(d) Employee benefits expense	4,232.54	5,086.01	3,852.29	16,934.52
	(e) Depreciation and amortisation expense	406.89	423.71	428.35	1,742.64
	(f) Selling, marketing and distribution	1,264.93	2,234.57	2,001.93	7,194.29
	(g) Other expenses	2,384.60	3,071.95	2,171.46	10,696.60
	Total expenses	12,763.84	15,985.13	13,097.34	56,474.13
3	Profit/ (loss) from operations before other income, finance costs and exceptional items (1-2)	1,190.24	(103.09)	100.34	(100.90)
4	Other income	156.20	209.29	171.31	677.27
5	Profit/ (loss) from ordinary activities before finance costs and exceptional items (3+4)	1,346.44	106.20	271.65	576.37
6	Finance costs	-	-	-	-
7	Profit/ (loss) from ordinary activities after finance costs but before exceptional items (5-6)	1,346.44	106.20	271.65	576.37
8	Exceptional items	-	-	-	-
9	Profit/ (loss) from ordinary activities before tax (7+8)	1,346.44	106.20	271.65	576.37
10	Tax expense	289.63	50.47	-	50.47
11	Net profit/(loss) from ordinary activities after tax (9-10)	1,056.81	55.73	271.65	525.90
12	Extraordinary item	-	-	-	-
13	Net profit/(loss) for the period (11-12)	1,056.81	55.73	271.65	525.90
14	Paid-up equity share capital (Face value of Rs 2 per equity share)	500.00	500.00	500.00	500.00
15	Reserves excluding revaluation reserves as per the balance sheet of previous accounting year				15,101.43
16	Basic and diluted earnings per share (of Rs 2 each) [not annualised] See accompanying note to the Financial Results	4.23	0.22	1.09	2.10

Notes:

- The above statement of financial results was reviewed by the Audit Committee and having been recommended for approval, was approved by the Board of Directors of the Company at their meeting held on 9 August 2016.
- The Company's sole reportable business segment is - 'Healthcare'. The other segments are not material and are hence disclosed as 'Others'. 'Others' comprise service income pertaining to clinical trials.
- AstraZeneca Pharmaceuticals AB, Sweden, the promoter of the Company vide its letter dated 1 March 2014, had proposed voluntary delisting of equity shares from stock exchanges ('Delisting Proposal'). The Board of Directors of the Company at their meeting held on 15 March 2014, had accorded approval for the Delisting Proposal. Further, the Delisting Proposal has been approved by the requisite majority of shareholders of the Company as required under Regulation 8 of SEBI (Delisting of Equity Shares) Regulations, 2009. Securities Exchange Board of India (SEBI) in its Order dated 24 June 2014 has issued directions to Bombay Stock Exchange and National Stock Exchange to closely monitor the entire delisting process of the Company and the Company shall finally purchase shares from the public shareholders in the delisting offer only after seeking approval from Bombay Stock Exchange and National Stock Exchange. The Company has received in-principle approval of National Stock Exchange and Bombay Stock Exchange, for voluntary delisting of equity shares from the said exchanges. A writ petition had been filed by two shareholders of the Company before the Honourable High Court of Judicature at Bombay ('the Court'), seeking inter-alia an order from the Court, restraining the Company and AstraZeneca Pharmaceuticals AB, Sweden ('AZPAB') from implementing the Delisting Proposal. The Court which heard the petition on 8 October 2014 has disposed off the same, with the directions that the Petitioners as well as the Company and AZPAB are at liberty to prefer appeal against SEBI Order dated 24 June 2014, to the Securities Appellate Tribunal (SAT), within six weeks and until the SAT hears and disposes of the Petitioners' appeal, the Company and AZPAB shall not take any further steps in the process of delisting of equity shares of the Company. The SAT was requested to hear and decide the appeals as expeditiously as possible and preferably by 28 February 2015. Further, an appeal has also been filed by two shareholders of the Company before the SAT, Mumbai, against part of SEBI's Order dated 24 June 2014, in relation to Delisting Proposal. The case was posted for hearing on multiple dates during the year ended 31 March 2015. At the hearing held on 5 May 2015, the SAT posted the matter to be heard on 9 July 2015 which was subsequently rescheduled for hearing on 11 August 2015. In the final hearing held on 11 September 2015, the SAT has disposed off the appeal directing SEBI to complete the investigation within a period of six months from date of its order and pass appropriate order on merits. The SAT has further directed the Company and the Promoter not to proceed with the delisting of equity shares till the completion of investigation and passing of the above mentioned order on merits by SEBI. Also the SAT has directed the Company and the Promoters that if the order passed by SEBI on merits is adverse to the appellants, then the said order shall not be given effect to from the date of passing the said order till it is communicated to the appellants and four weeks thereafter.
- The figures for the preceding quarter ended 31 March 2016 as reported in this financial results are the balancing figures between audited figures in respect of the full previous year and the published year to date figures upto the end of the third quarter of the previous financial year. Also figures upto the third quarter of the relevant financial year were only reviewed and not subjected to audit. The above statement of financial results has been reviewed by the statutory auditors. The statutory auditors have issued an unqualified review report. The review report has been filed with the stock exchange and is also available on the Company's website.

By Order of the Board of Directors
For AstraZeneca Pharma India Limited


Sanjay Mureshwar,
Managing Director

Mumbai
Dated: 9 August 2016

AstraZeneca Pharma India Limited

Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045

Segment wise revenue, results and capital employed

(Rs in lakhs)

Sl.no.	Particulars	3 months ended 30/06/2016 (Unaudited)	3 months ended 31/03/2016 (Audited)²	3 months ended 30/06/2015 (Unaudited)	Previous year ended 31/03/2016 (Audited)
1	Segment revenue				
	(a) Healthcare	13,594.34	15,438.15	13,055.22	55,402.82
	(b) Others	359.74	443.89	142.46	970.41
	Net sales/income from operations	13,954.08	15,882.04	13,197.68	56,373.23
2	Segment results				
	Profit/(loss) before tax and interest				
	(a) Healthcare	1,179.15	(113.27)	94.28	(135.16)
	(b) Others	11.09	10.18	6.06	34.26
	Total	1,190.24	(103.09)	100.34	(100.90)
	Add: Other income	156.20	209.29	171.31	677.27
	Add: Exceptional item	-	-	-	-
	Less: Interest	-	-	-	-
	Total profit/(loss) before tax	1,346.44	106.20	271.65	576.37
3	Capital employed				
	(a) Healthcare	7,061.88	6,791.87	6,325.29	6,791.87
	(b) Others	(339.13)	(165.94)	(133.79)	(165.94)
	(c) Unallocated	9,935.49	8,975.50	9,155.68	8,975.50
	Total	16,658.24	15,601.43	15,347.18	15,601.43

Notes :

- 1 Certain assets and liabilities of the Healthcare segment are interchangeably used for other segments for limited purposes. Identification of such assets and liabilities is not feasible. Hence, such assets have not been allocated to any segment.
- 2 The figures for the preceding quarter ended 31 March 2016 as reported in this financial results is the balancing figure between audited figures in respect of the full previous year and the published year to date figures upto the end of the third quarter of the previous financial year. Also figures upto the third quarter of the relevant financial year were only reviewed and not subjected to audit.

